| To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313) (NCT04551066) | Incyte Corporation | 2021-05-24 |
| Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients (NCT04824092) | Incyte Corporation | 2021-05-11 |
| A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Vitiligo (NCT04818346) | Incyte Corporation | 2021-05-06 |
| To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Renal Function and Renal Impairment. (NCT04831996) | Incyte Corporation | 2021-05-04 |
| A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. (NCT04680052) | Incyte Corporation | 2021-04-15 |
| Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors (NCT04272034) | Incyte Corporation | 2021-03-26 |
| INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders (NCT04455841) | Incyte Corporation | 2021-03-19 |
| A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib (NCT04640025) | Incyte Corporation | 2021-03-10 |
| Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms (NCT04279847) | Incyte Corporation | 2021-02-23 |
| INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors (NCT04580485) | Incyte Corporation | 2021-02-03 |
| Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy. (NCT04463771) | Incyte Corporation | 2021-01-26 |
| Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2). (NCT04472429) | Incyte Corporation | 2021-01-12 |
| Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo (NCT04530344) | Incyte Corporation | 2020-09-24 |
| Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors (NCT04242199) | Incyte Corporation | 2020-09-04 |
| To Assess the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa (NCT04476043) | Incyte Corporation | 2020-08-25 |
| Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465) (NCT04509700) | Incyte Corporation | 2020-08-03 |
| INCMGA00012 in Combination With Chemoradiation in Participants With Stage III Non-Small Cell Lung Cancer (POD1UM-301) (NCT04203511) | Incyte Corporation | 2020-07-31 |
| Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies (NCT04370704) | Incyte Corporation | 2020-07-27 |
| Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205) (NCT04003610) | Incyte Corporation | 2020-05-14 |
| A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy (NCT04071366) | Incyte Corporation | 2020-02-07 |
| Safety and Efficacy of Itacitinib in Participants With Bronchiolitis Obliterans Syndrome Following Lung Transplantation (NCT03978637) | Incyte Corporation | 2020-02-04 |
| Safety and Efficacy of Itacitinib in Combination With Corticosteroids for Treatment of Graft-Versus-Host Disease in Pediatric Subjects (NCT03721965) | Incyte Corporation | 2019-12-31 |
| Efficacy and Safety of Pemigatinib in Participants With Solid Tumors With FGFR Mutations or Translocations (FIGHT-208) (NCT04003623) | Incyte Corporation | 2019-10-31 |
| Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) (NCT03822117) | Incyte Corporation | 2019-10-17 |
| Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) (NCT04057573) | Incyte Corporation | 2019-10-03 |
| INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma (NCT03837509) | Incyte Corporation | 2019-09-25 |
| Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1) (NCT04052425) | Incyte Corporation | 2019-09-20 |
| INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105) (NCT03920839) | Incyte Corporation | 2019-07-15 |
| A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma (NCT03656536) | Incyte Corporation | 2019-06-03 |
| A Maximum Use Trial of Ruxolitinib Cream in Adolescent and Adult Participants With Atopic Dermatitis (NCT03920852) | Incyte Corporation | 2019-05-30 |
| A Study of the Safety and Tolerability of INCB050465 in Pemphigus Vulgaris (NCT03780166) | Incyte Corporation | 2019-03-01 |
| A Study of INCB050465 in Primary Sjögren's Syndrome (NCT03627065) | Incyte Corporation | 2019-02-28 |
| A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201) (NCT03599713) | Incyte Corporation | 2019-02-25 |
| GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (NCT03584516) | Incyte Corporation | 2019-01-17 |
| A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203) (NCT03679767) | Incyte Corporation | 2019-01-09 |
| Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (TRuE AD1) - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis (NCT03745638) | Incyte Corporation | 2018-12-20 |
| TRuE AD2 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis (NCT03745651) | Incyte Corporation | 2018-12-20 |
| A Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors (NCT03762447) | Incyte Corporation | 2018-12-10 |
| A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma (NCT03688152) | Incyte Corporation | 2018-12-03 |
| A Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia (NCT03538041) | Incyte Corporation | 2018-11-21 |
| A Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa (NCT03607487) | Incyte Corporation | 2018-10-15 |
| A Study of INCMGA00012 in Squamous Carcinoma of the Anal Canal Following Platinum-Based Chemotherapy (POD1UM-202) (NCT03597295) | Incyte Corporation | 2018-10-08 |
| A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies (NCT03652077) | Incyte Corporation | 2018-09-24 |
| A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies (NCT03522142) | Incyte Corporation | 2018-08-27 |
| INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors (NCT03589651) | Incyte Corporation | 2018-08-17 |
| A Study of INCB050465 in Japanese Subjects With Previously Treated B-Cell Lymphoma (CITADEL-111) (NCT03314922) | Incyte Corporation | 2018-08-02 |
| INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112) (NCT03424122) | Incyte Corporation | 2018-07-02 |
| A Study of INCB059872 in Relapsed or Refractory Ewing Sarcoma (NCT03514407) | Incyte Corporation | 2018-06-27 |
| A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208) (NCT03347123) | Incyte Corporation | 2018-03-21 |
| Safety of Itacitinib in Combination With Corticosteroids for Treatment of Steroid-Naive Acute Graft-Versus-Host Disease in Japanese Subjects (NCT03497273) | Incyte Corporation | 2018-03-20 |
| A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors (NCT03361228) | Incyte Corporation | 2018-03-01 |
| GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease (NCT03320642) | Incyte Corporation | 2018-02-27 |
| A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis (NCT03144687) | Incyte Corporation | 2018-01-26 |
| A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06) (NCT03322566) | Incyte Corporation | 2018-01-09 |
| Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer (NCT03348904) | Incyte Corporation | 2017-12-27 |
| Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma (NCT03374488) | Incyte Corporation | 2017-12-22 |
| A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204) (NCT03144674) | Incyte Corporation | 2017-12-18 |
| Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05) (NCT03322540) | Incyte Corporation | 2017-12-15 |
| Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310) (NCT03342352) | Incyte Corporation | 2017-12-15 |
| Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302) (NCT03260894) | Incyte Corporation | 2017-12-07 |
| Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304) (NCT03358472) | Incyte Corporation | 2017-12-01 |
| A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors (NCT03314935) | Incyte Corporation | 2017-11-21 |
| A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor (NCT03235544) | Incyte Corporation | 2017-11-20 |
| Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272) (NCT03123588) | Incyte Corporation | 2017-11-14 |